Health Care [ 2/12 ] | Biotechnology [ 8/73 ]
NASDAQ | Common Stock
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF).
It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; and SION-719 and SION-451, which are nucleotide-binding domain 1 stabilizers in Phase 1 trial.
The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021.
Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 11, 25 | -0.41 | -0.52 Increased by +21.15% |
| May 13, 25 | -0.62 | -0.45 Decreased by -37.78% |
| Mar 20, 25 | -3.38 | -2.68 Decreased by -26.12% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 25 | 0.00 Decreased by N/A% | -18.07 M Decreased by -111.27% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 0.00 Decreased by N/A% | -16.48 M Decreased by -39.12% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 0.00 Decreased by N/A% | -15.85 M Decreased by -33.45% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 - | -25.44 M - | Decreased by N/A% - |
| Jun 30, 24 | 0.00 - | -8.55 M - | Decreased by N/A% - |
| Mar 31, 24 | 0.00 - | -11.85 M - | Decreased by N/A% - |
| Dec 31, 23 | 0.00 - | -11.88 M - | Decreased by N/A% - |